PID1 acts as an indicator for assessing immunomodulatory treatment in sepsis and can function as a stratification tool to monitor the effectiveness of IFN-γ therapy prior to immunostimulatory intervention in sepsis (58). The gene discussed is IFNG; the disease is Sepsis.